This technology is a self-reportable measure of perceived cognitive change that can be used to track cognitive outcomes for treatment trials in neurologic populations.
Current neuropsychological tests for multiple sclerosis assess objective impairment in controlled settings but fail to align with patients’ self-reported cognitive decline. Test administration under minimal distractions in one-on-one settings limits the ability to capture real-world cognitive challenges. Further, the existing measures focus on present cognition rather than detecting subtle cognitive changes over time.
This technology introduces the Cognitive Change Scale (CCS), which is a self-reported survey designed to assess cognitive changes over the past year. It captures subjective cognitive function change over time, incorporating language and executive function domains alongside traditional measures. Overall, the CCS provides a valuable tool for tracking cognitive change in neurologic populations for whom cognitive changes may be subtle or difficult to detect.
This technology has been validated in patients with multiple sclerosis.
Victoria Leavitt, Ph.D., F.A.A.N.
IR CU25123
Licensing Contact: Joan Martinez
